Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840278 · ClinicalTrials.gov registry record · Phase 2
The Bihormonal iLet Bionic Pancreas Feasibility Study
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03840278: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03840278 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03840278, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Our objective is to evaluate the function of the bihormonal configuration of the ILet bionic pancreas delivering dasiglucagon when compared to the insulin-only configuration of the ILet bionic pancreas in a home-use study in adults with type 1 diabetes.
Primary Outcome
Goal for the percentage of time that valid CGM glucose readings are captured by the iLet is ≥80%.
Interventions
- DRUG Dasiglucagon
- DEVICE Bihormonal iLet Bionic Pancreas
- DEVICE Insulin-only Bionic Pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
What the finished NCT03840278 record still lists
NCT03840278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Dasiglucagon is the first listed.
NCT03840278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03840278 about?
NCT03840278 is a clinical study titled "The Bihormonal iLet Bionic Pancreas Feasibility Study". Our objective is to evaluate the function of the bihormonal configuration of the ILet bionic pancreas delivering dasiglucagon when compared to the insulin-only configuration of the ILet bionic pancreas in a home-use study in adults with type 1 diabetes.
What is the current status of trial NCT03840278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-05-15. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT03840278?
The interventions under investigation include: Dasiglucagon (DRUG), Bihormonal iLet Bionic Pancreas (DEVICE), Insulin-only Bionic Pancreas (DEVICE).
Who is sponsoring clinical trial NCT03840278?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03840278's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI